Dosing Commences for CBD Topical Osteoarthritis Study
Avecho today announced that it has commenced dosing for its proof-of-concept Phase IIa study, in collaboration with the Lambert Initiative for Cannabinoid Therapeutics, examining the use of topical CBD for the management of arthritis pain in the hand.
Fifteen patients suffering painful arthritis of the fingers or thumb have been enrolled in the study, and will apply a proprietary formulation vehicle incorporating TPM® technology to their painful joints daily over four weeks.
Avecho CEO, Dr Paul Gavin said:
“Osteoarthritis (OA) is a chronic and poorly managed pain condition, with limited treatments available. We are proud to be exploring the potential of one of Avecho’s proprietary formulation vehicles incorporating our TPM® technology, to address this unmet need in pain management. Commencement of patient dosing is an important milestone in our ongoing efforts to understand and quantify how it could help.”